

ASX RELEASE

8 September 2025

**Change of Director's Interest Notice – Appendix 3Y: Dr Christopher Burns**

Appendix 3Y Change of Director's Interest Notice for Dr. Christopher Burns is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Amplia Therapeutics Limited</b>
<b>ABN</b>	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Christopher John Burns</b>
<b>Date of last notice</b>	20 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	1 September 2025 re Allotment of Shares and Options  6 September 2025 re Expiry of Options
<b>No. of securities held prior to change</b>	4,068,617 Fully Paid Ordinary Shares  535,000 Unlisted Options Exercise Price A\$0.2533 Expiry Date 6 Sep 2025  2,500,000 Unlisted Options Exercise Price \$0.135 Expiry Date 5 June 2028  260,869 Listed Options Ex Price \$0.1725 Exp 31 Oct 2027
<b>Class</b>	a. Ordinary Shares b. Options Nil Ex Price Expire 30 Sep 2028 c. Options Ex Price \$0.2533 Expire 6 Sep 2025

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	<ul style="list-style-type: none"> <li>a. 86,957 Ordinary Shares</li> <li>b. 447,000 Options – Nil Ex Price Exp 30 Sep 2028</li> </ul>
<b>Number disposed</b>	<ul style="list-style-type: none"> <li>c. 535,000 Unlisted Options Exercise Price A\$0.2533 Expiry Date 6 Sep 2025</li> </ul>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> <li>a. Participation in Capital Raise – Director Placement Shares \$0.23 per share following approval by shareholders at AGM held 27 August 2025</li> <li>b. Allotment of Options for Nil Consideration following approval by shareholders at AGM held 27 August 2025</li> <li>c. Expiry of Options – not exercised, nil consideration</li> </ul>
<b>No. of securities held after change</b>	<p>4,155,574 Fully Paid Ordinary Shares</p> <p>447,000 Unlisted Options - Nil Exercise Price Expiry Date 30 Sep 2028</p> <p>2,500,000 Unlisted Options Exercise Price \$0.135 Expiry Date 5 June 2028</p> <p>260,869 Listed Options Ex Price \$0.1725 Exp 31 Oct 2027</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ul style="list-style-type: none"> <li>a. Participation in Capital Raise – Director Placement Shares as approved by shareholders at AGM held 27 August 2025.</li> <li>b. Allotment of Options for Nil Consideration following approval by shareholders at AGM held 27 August 2025</li> <li>c. Expiry of Options – not exercised, nil consideration</li> </ul>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

8 September 2025

---

+ See chapter 19 for defined terms.

For personal use only